Singapore-headquartered Juniper Therapeutix, a science-led healthcare company focused on commercializing novel therapies, announced its agreement with Ping-An Shionogi Hong Kong, a group company of Shionogi & Co., Ltd, to license the rights to Ensitrelvir Fumaric Acid (“Ensitrelvir”) for Singapore. Juniper Biologics has applied for private patient access with the Health Sciences Authority (HSA) of the Republic of Singapore for…